TrivarX (ASX:TRI) Buyback Yield % : -39.46 (As of Jun. 06, 2024)

View and export this data going back to 2001. Start your Free Trial

What is TrivarX Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

TrivarX's current buyback yield was -39.46%.

TrivarX Buyback Yield % Historical Data

The historical data trend for TrivarX's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX Buyback Yield % Chart

TrivarX Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Buyback Yield %

Get a 7-Day Free Trial

-34.92

-71.69

-39.58

-81.75

-55.12

TrivarX Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Buyback Yield %	Get a 7-Day Free Trial															-21.56	-104.38	-23.49	-75.95	-58.39

Competitive Comparison of TrivarX's Buyback Yield %

For the Health Information Services subindustry, TrivarX's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TrivarX's Buyback Yield % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TrivarX's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where TrivarX's Buyback Yield % falls into.

TrivarX Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

TrivarX's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	2.507)	/	4.54792
	=	-55.12%

TrivarX's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (-0.193	+	3.154)	*	2	/	10.14237
	=	-58.39%

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.

TrivarX Buyback Yield % Related Terms

Thank you for viewing the detailed overview of TrivarX's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

TrivarX (ASX:TRI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (ASX:TRI) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

MDBIF:USA

Address

647 Beaufort Street, Mount Lawley, WA, AUS, 6050

Website

https://www.medibio.com.au

TrivarX Ltd Formerly Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets; Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.